Cara Therapeutics, Inc. (CARA) Monday announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia paresthetica (NP) and significantly reduce its operating expenses. These measures will extend the company's cash runway into 2026, enabling the expected completion of the NP clinical program.Enrollment in the Phase 2/3 clinical program evaluating oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with NP, known as KOURAGE, is progressing ahead of the company's projections.

Cara Therapeutics，Inc.（Cara）周一宣布，将把资源集中在notalgia paresthetica（NP）的口服difelikefalin 2/3期临床计划上，并大幅降低运营费用。这些措施将把公司的现金跑道延长到2026年，从而有望完成NP临床计划。参与评估口服difelikefalin治疗NP患者中度至重度瘙痒症（称为KOURAGE）的2/3期临床计划的进展优于该公司的预测。

A data readout from the dose-finding portion of the program is expected in the third quarter of 2024. Final topline results from the first pivotal study are expected by the end of 2025 with the second pivotal study results in early 2026..

预计2024年第三季度将从该计划的剂量发现部分读出数据。第一项关键研究的最终结果预计将于2025年底公布，第二项关键研究结果将于2026年初公布。。

'We are sharpening our clinical focus on the rapidly progressing Phase 2/3 study in NP, which we believe is the therapeutic indication with the greatest commercial potential for oral difelikefalin,' said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. 'Following careful consideration, we have decided to discontinue our work in advanced chronic kidney disease (CKD).

Cara Therapeutics总裁兼首席执行官克里斯托弗·波斯纳（ChristopherPosner）说：“我们正在将临床重点放在NP快速进展的2/3期研究上，我们认为这是口服difelikefalin具有最大商业潜力的治疗指征。”经过仔细考虑，我们决定停止对晚期慢性肾病（CKD）的研究。

I would like to thank the patients and investigators who have participated in our advanced CKD clinical program, as well as our employees for their commitment to transforming the lives of CKD patients suffering from pruritus.'Posner continued, 'Unfortunately, as a result of the difficult decision to restructure the Company, many of our talented team members will depart the organization.

我要感谢参与我们先进CKD临床计划的患者和研究人员，以及我们的员工，感谢他们致力于改变患有瘙痒症的CKD患者的生活。”波斯纳继续说，“不幸的是，由于重组公司的艰难决定，我们许多有才能的团队成员将离开公司。

I am deeply grateful for their dedicated service and support of our mission. We expect the changes we are making to extend our cash runway into 2026, allowing us to reach all expected key value-inflection milestones in the NP clinical program.' For comments and feedback contact: editorial@rttnews.comBusiness News.

我非常感谢他们对我们特派团的奉献服务和支持。我们预计，我们正在进行的改变将把我们的现金跑道延长到2026年，使我们能够达到NP临床计划中所有预期的关键价值转折里程碑。”如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In October 2023

2023年10月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in August 2023

2023年8月美国食品和药物管理局（FDA）决定生物技术股